πŸ‡ΊπŸ‡Έ FDA

Intelligence Platform

Patents

Browse 31 pharma-relevant US patents (A61K/A61P) linked to tracked companies. Patent cliff and LOE intelligence for BD teams.

29,054 patents indexed
patent

US 12188005

NK cells with an increased antibody-dependent cellular toxicity (ADCC) against tumors

The United States of America, as represented by the Secretary, Department of Health and Human Services Β· Granted Tue Jan 07 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jan 02 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12129476

Methods for measuring the potency of AADC viral vectors

VOYAGER THERAPEUTICS, INC. Β· Granted Tue Oct 29 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Oct 24 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11975056

AADC polynucleotides for the treatment of Parkinson's disease

VOYAGER THERAPEUTICS, INC. Β· Granted Tue May 07 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon May 02 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11976122

Anti-IL13RΞ±2 antibodies

ADC THERAPEUTICS SA Β· Granted Tue May 07 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon May 02 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11938192

Dosage regimes for the administration of an anti-CD19 ADC

ADC THERAPEUTICS SA Β· Granted Tue Mar 26 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Mar 21 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11813335

Pyrrolobenzodiazepine-antibody conjugates

ADC THERAPEUTICS SA Β· Granted Tue Nov 14 2023 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Nov 09 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11759506

AADC polynucleotides for the treatment of Parkinson's disease

VOYAGER THERAPEUTICS, INC. Β· Granted Tue Sep 19 2023 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Sep 14 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11702473

Site-specific antibody-drug conjugates

ADC THERAPEUTICS SA Β· Granted Tue Jul 18 2023 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jul 13 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11690918

Pyrrolobenzodiazepine-anti-CD22 antibody conjugates

ADC THERAPEUTICS SA Β· Granted Tue Jul 04 2023 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jun 29 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11596696

Combination therapy with an anti-CD25 antibody-drug conjugate

ADC THERAPEUTICS SA Β· Granted Tue Mar 07 2023 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Mar 02 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11426467

Dosage regimes for the administration of an anti-CD25 ADC

ADC THERAPEUTICS SA Β· Granted Tue Aug 30 2022 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Aug 25 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11384098

Pyrrolobenzodiazepine-antibody conjugates

ADC THERAPEUTICS SA Β· Granted Tue Jul 12 2022 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jul 07 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11318211

Dosage regimes for the administration of an anti-CD19 ADC

ADC THERAPEUTICS SA Β· Granted Tue May 03 2022 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Apr 28 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11160872

Pyrrolobenzodiazepine-antibody conjugates

ADC THERAPEUTICS SA Β· Granted Tue Nov 02 2021 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Oct 28 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11084872

Method for treating breast cancer

ADC THERAPEUTICS SA Β· Granted Tue Aug 10 2021 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Aug 05 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11027000

AADC polynucleotides for the treatment of Parkinson's disease

VOYAGER THERAPEUTICS, INC. Β· Granted Tue Jun 08 2021 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jun 03 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 10898585

Gene therapy for AADC deficiency

PTC THERAPEUTICS, INC. Β· Granted Tue Jan 26 2021 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jan 21 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 10813952

NK cells with an increased antibody-dependent cellular toxicity (ADCC) against tumors

The United States of America, as represented by the Secretary, Department of Health and Human Services Β· Granted Tue Oct 27 2020 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Oct 22 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 10799596

Pyrrolobenzodiazepine-antibody conjugates

ADC THERAPEUTICS SA Β· Granted Tue Oct 13 2020 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Oct 08 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 10780096

Pyrrolobenzodiazepine-antibody conjugates

ADC THERAPEUTICS SA Β· Granted Tue Sep 22 2020 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Sep 17 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 10722594

Pyrrolobenzodiazepine-anti-CD22 antibody conjugates

ADC THERAPEUTICS SA Β· Granted Tue Jul 28 2020 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jul 23 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 10597450

Antibodies against kidney associated antigen 1 and antigen binding fragments thereof

ADC THERAPEUTICS SA Β· Granted Tue Mar 24 2020 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Mar 19 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 10544223

Combination therapy with an anti-axl antibody-drug conjugate

ADC THERAPEUTICS SA Β· Granted Tue Jan 28 2020 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jan 23 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 10335466

AADC polynucleotides for the treatment of parkinson's disease

VOYAGER THERAPEUTICS, INC. Β· Granted Tue Jul 02 2019 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jun 27 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted